A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

Phase 1

Recruiting

• Conditions: Healthy Volunteers
• Interventions: Drug: TS-172 20 mg; Drug: TS-172 90 mg; Drug: Moxifloxacin; Drug: Placebo

• Registration Number: NCT06837155
• Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Brief Summary

A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-02-16
• Study First Submitted QC: 2025-02-16
• Study First Posted: 2025-02-20
• Status Verified: 2025-03
• Study Start: 2025-03-03
• Last Update Submitted: 2025-03-13
• Last Update Posted: 2025-03-18
• Primary Completion: 2025-05-20
• Study Completion: 2025-05-26

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
TS-172 20 mg	TS-172 20 mg	-
TS-172 90 mg	TS-172 90 mg	-
Moxifloxacin	Moxifloxacin	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs	Up to 24 hours postdose during each period

Trial Locations

Locations (1)

Taisho Pharmaceutical Co., Ltd selected site; 🇯🇵 Tokyo, Japan